Resmed Inc (RMD) Stock AnalysisRMDStock AnalysisResmed Inc

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

ResMed Inc (RMD) is currently priced at $240.33, which is near the recent analyst price targets of $244 and $230. The RSI is at 79.279, indicating that the stock is overbought, which suggests caution for new buyers. The gross margin stands at 58.12%, reflecting solid profitability, but the operating margin has decreased to 30.7%, indicating potential challenges ahead. The main risk is the recent decrease in operating margins due to rising costs, which could impact future profitability.

10 analysts cover RMD: 4 rate it Buy, 2 Hold and 4 Sell. The average price target is 294.00.